4.05
0.01 (0.25%)
| Penutupan Terdahulu | 4.04 |
| Buka | 4.02 |
| Jumlah Dagangan | 932,093 |
| Purata Dagangan (3B) | 2,424,656 |
| Modal Pasaran | 223,808,272 |
| Harga / Pendapatan (P/E Ke hadapan) | 8.98 |
| Harga / Jualan (P/S) | 3.91 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 May 2025 - 12 May 2025 |
| Margin Operasi (TTM) | -79,817.02% |
| EPS Cair (TTM) | -1.42 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 32.30% |
| Nisbah Semasa (MRQ) | 0.290 |
| Aliran Tunai Operasi (OCF TTM) | -30.76 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -22.81 M |
| Pulangan Atas Aset (ROA TTM) | -633.94% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Checkpoint Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.50 |
|
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.83% |
| % Dimiliki oleh Institusi | 33.01% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Wealth Enhancement Advisory Services, Llc | 31 Dec 2024 | 425,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 4.80 (D. Boral Capital, 18.52%) | Beli |
| Median | 4.10 (1.24%) | |
| Rendah | 4.10 (Lake Street, 1.24%) | Pegang |
| 4.10 (HC Wainwright & Co., 1.24%) | Pegang | |
| Purata | 4.33 (6.91%) | |
| Jumlah | 1 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 4.01 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 31 Mar 2025 | 4.80 (18.52%) | Beli | 4.04 |
| 10 Mar 2025 | 4.80 (18.52%) | Beli | 3.98 | |
| HC Wainwright & Co. | 11 Mar 2025 | 4.10 (1.23%) | Pegang | 4.00 |
| Lake Street | 10 Mar 2025 | 4.10 (1.23%) | Pegang | 3.98 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Mar 2025 | Pengumuman | Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates |
| 09 Mar 2025 | Pengumuman | Sun Pharma to Acquire Checkpoint Therapeutics |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |